AstraZeneca's blood thinner Brilinta/Brilique demonstrates cost effectiveness; new Nexium indication filed in Japan

24 October 2011

Data from eight countries shows that using Anglo-Swedish drug major AstraZeneca’s (LSE: AZN) Brilique/Brilinta (ticagrelor) plus aspirin to treat acute coronary syndrome (ACS) patients for one year is associated with cost-savings, gain in quality-adjusted life years, and life-years gained compared to treatment with both generic and branded clopidogrel plus aspirin.

These results, from health economics sub-studies from the PLATO trial, will be presented at the upcoming International Society for Pharmacoeconomics and Outcomes Research (ISPOR) European Union meeting, November 5-8 in Madrid, Spain. They are driven by a reduced rate of mortality. In the European Union, Brilique is indicated for the prevention of atherothrombotic events in adult patients with ACS. The drug was also approved by the US Food and Drug Administration this summer (The Pharma Letter July 21).

As cost effective as Plavix

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK